|

Dasatinib Clinical Trials

19 actively recruiting trials across 8 locations

No change since June 2026

Also known as: 6-MP, Asparaginase, BMS 354825, BMS-354825, BMS354825 +14 more

Pipeline

Early 1: 2Phase 1: 1Phase 2: 12Phase 4: 2Phase 1/2: 1Phase 2/3: 1

Top Sponsors

St. Jude Children's Research Hospital2
Mayo Clinic2
Wei Zhao1
University of Chicago1
Princess Maxima Center for Pediatric Oncology1

Indications

Cancer19
Acute Lymphoblastic Leukemia4
Chronic Phase Chronic Myelogenous Leukemia2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive1
BCR-ABL1 Positive1

Other8 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Phase 2

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

Phase 2

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Phase 1/2

Newly-diagnosed Pediatric T-cell ALL Protocol

Phase 2/3

Pilot Trial for Treatment of Recurrent Glioblastoma

Early 1

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

Birmingham, Alabama2 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

University of Alabama/Children's of Alabama

Phase 2

Chicago, Illinois2 trials

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

University of Chicago Comprehensive Cancer Center

Phase 1

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago Medical Center

Phase 2

Rochester, Minnesota2 trials

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic in Rochester

Phase 2

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

Mayo Clinic in Rochester

Early 1

San Diego, California1 trial

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Rady Children's Hospital

Phase 2

Ann Arbor, Michigan1 trial

Asciminib Roll-over Study

Michigan Med University of Michigan

Phase 4

Detroit, Michigan1 trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The Barbara Ann Karmanos Cancer Institute

Phase 2

Tulsa, Oklahoma1 trial

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Saint Francis Children's Hospital

Phase 2

Houston, Texas1 trial

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.